CoChat

Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O 6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report

Broniscer, Alberto, Gururangan, Sridharan, MacDonald, Tobey J., Goldman, Stewart, Packer, Roger J., Stewart, Clinton F., Wallace, Dana, Danks, Mary K., Friedman, Henry S., Poussaint, Tina Y., Kun, Larry E., Boyett, James M., Gajjar, Amar, for the Pediatric Brain Tumor Consortium · 2007 · Clinical Cancer Research
Cited by 67

The DOI matches its Crossref record.

Abstract

Purpose: To estimate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of escalating doses of temozolomide combined with O6-benzylguanine in patients ≤21 years with recurrent brain tumors. Experimental Design: Treatment strata consisted of patients who had previously received no or local radiotherapy (Str1) and patients who had undergone craniospinal radiotherapy or myeloablative chemotherapy (Str2). One-hour i.v. administration of O6-benzylguanine at 120 mg/m2 was followed by 48-h continuous infusion at 30 mg/m2/day. Single-dose temozolomide at five dosage levels (267, 355, 472, 628, and 835 mg/m2) was given at least 6 h after completion of O6-benzylguanine bolus. Treatment was repeated after recovery from toxicities at least 4 weeks apart for a maximum of 12 courses. Dose escalation followed the modified continual reassessment method. Pharmacokinetic analyses of temozolomide and 5-triazeno imidazole carboxamide (MTIC) were done in 28 patients. Results: A total of 44 and 26 eligible patients were enrolled on Str1 and Str2, respectively. Median age at study entry in each stratum was 8.6 and 11.3 years, respectively. Predominant diagnoses were high-grade/brainstem glioma in Str1 and medulloblastoma in Str2. Whereas the estimated MTDs of temozolomide for Str1 and Str2 were 562 and 407 mg/m2, respectively, the doses recommended for phase II investigations are 472 and 355 mg/m2, respectively. DLTs were predominantly neutropenia and thrombocytopenia. Three patients with gliomas experienced centrally confirmed partial responses to therapy. Four patients completed all planned therapy. Temozolomide and MTIC exposures were statistically associated with temozolomide dosage. Conclusions: The current schedule of temozolomide and O6-benzylguanine is safe and showed modest activity against recurrent brain tumors in children.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-1016

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 67

Metadata

Authors
Broniscer, A., Gururangan, S., MacDonald, T. J., Goldman, S., Packer, R. J., Stewart, C. F., Wallace, D., Danks, M. K., Friedman, H. S., Poussaint, T. Y., Kun, L. E., Boyett, J. M., Gajjar, A., & for the Pediatric Brain Tumor Consortium
Venue
Clinical Cancer Research
Published
2007-11-15
Volume
13
Issue
22
Pages
6712-6718
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2073823496
Cited by
67
References
0
FWCI
3.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O 6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1016
The paper
Broniscer, A., Gururangan, S., MacDonald, T. J., Goldman, S., Packer, R. J., Stewart, C. F., Wallace, D., Danks, M. K., Friedman, H. S., Poussaint, T. Y., Kun, L. E., Boyett, J. M., Gajjar, A., & for the Pediatric Brain Tumor Consortium. (2007). Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O 6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.